Activated Protein C Protects Against Diabetic Nephropathy By Inhibiting Endothelial And Podocyte Apoptosis

Data providing direct evidence for a causative link between endothelial dysfunction, microvascular disease and diabetic end-organ damage are scarce. Here we show that activated protein C (APC) formation, which is regulated by endothelial thrombomodulin, is reduced in diabetic mice and causally linked to nephropathy. Thrombomodulin-dependent APC formation mediates cytoprotection in diabetic nephropathy by inhibiting glomerular apoptosis. APC prevents glucose-induced apoptosis in endothelial cells and podocytes, the cellular components of the glomerular filtration barrier. APC modulates the mitochondrial apoptosis pathway via the protease-activated receptor PAR-1 and the endothelial protein C receptor EPCR in glucose-stressed cells. These experiments establish a new pathway, in which hyperglycemia impairs endothelial thrombomodulin- dependent APC formation. Loss of thrombomodulin-dependent APC formation interrupts cross-talk between the vascular compartment and podocytes, causing glomerular apoptosis and diabetic nephropathy. Conversely, maintaining high APC levels during long-term diabetes protects against diabetic nephropathy. © 2007 Nature Publishing Group.131113491358Renal Data System: USRDS 1998 Annual Data Report (NIH Publ. No. 98-3176) (US Government Printing Office, Washington, DC, 1998)Wendt, T.M., RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy (2003) Am. J. Pathol, 162, pp. 1123-1137Haraldsson, B., Sorensson, J., Why do we not all have proteinuria? An update of our current understanding of the glomerular barrier (2004) News Physiol. Sci, 19, pp. 7-10Dalla Vestra, M., Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes (2003) Diabetes, 52, pp. 1031-1035Meyer, T.W., Bennett, P.H., Nelson, R.G., Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria (1999) Diabetologia, 42, pp. 1341-1344Esmon, C.T. Inflammation and the activated protein C anticoagulant pathway. Semin. Thromb. Hemost. 32 (Suppl. 1), 49-60 (2006)Riewald, M., Petrovan, R.J., Donner, A., Mueller, B.M., Ruf, W., Activation of endothelial cell protease activated receptor 1 by the protein C pathway (2002) Science, 296, pp. 1880-1882Cheng, T., Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective (2003) Nat. Med, 9, pp. 338-342Feistritzer, C., Riewald, M., Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation (2005) Blood, 105, pp. 3178-3184Finigan, J.H., Activated protein C mediates novel lung endothelial barrier enhancement: Role of sphingosine 1-phosphate receptor transactivation (2005) J. Biol. Chem, 280, pp. 17286-17293Borcea, V., Influence of ramipril on the course of plasma thrombomodulin in patients with diabetes mellitus (1999) Vasa, 28, pp. 172-180Fujiwara, Y., Tagami, S., Kawakami, Y., Circulating thrombomodulin and hematological alterations in type 2 diabetic patients with retinopathy (1998) J. Atheroscler. Thromb, 5, pp. 21-28Weiler-Guettler, H., A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state (1998) J. Clin. Invest, 101, pp. 1983-1991Hall, S.W., Nagashima, M., Zhao, L., Morser, J., Leung, L.L., Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains (1999) J. Biol. Chem, 274, pp. 25510-25516Festa, A., Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study (2000) Kidney Int, 58, pp. 1703-1710Isermann, B., The thrombomodulin-protein C system is essential for the maintenance of pregnancy (2003) Nat. Med, 9, pp. 331-337Mosnier, L.O., Griffin, J.H., Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor (2003) Biochem. J, 373, pp. 65-70Tewari, M., Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase (1995) Cell, 81, pp. 801-809Wang, J., Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria (2004) J. Biol. Chem, 279, pp. 19948-19954Kelly, K.J., Minocycline inhibits apoptosis and inflammation in a rat model of ischemic renal injury (2004) Am. J. Physiol. Renal Physiol, 287, pp. F760-F766Brownlee, M., Biochemistry and molecular cell biology of diabetic complications (2001) Nature, 414, pp. 813-820Zou, M.H., Shi, C., Cohen, R.A., High glucose via peroxynitrite causes tyrosine nitration and inactivation of prostacyclin synthase that is associated with thromboxane/prostaglandin H(2) receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells (2002) Diabetes, 51, pp. 198-203Yamaji, K., Activated protein C, a natural anticoagulant protein, has antioxidant properties and inhibits lipid peroxidation and advanced glycation end products formation (2005) Thromb. Res, 115, pp. 319-325Riewald, M., Ruf, W., Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling (2005) J. Biol. Chem, 280, pp. 19808-19814Goligorsky, M.S., Chen, J., Brodsky, S., Workshop: Endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide (2001) Hypertension, 37, pp. 744-748Endemann, D.H., Schiffrin, E.L., Endothelial dysfunction (2004) J. Am. Soc. Nephrol, 15, pp. 1983-1992Murata, I., Apoptotic cell loss following cell proliferation in renal glomeruli of Otsuka Long-Evans Tokushima Fatty rats, a model of human type 2 diabetes (2002) Am. J. Nephrol, 22, pp. 587-595Kumar, D., Robertson, S., Burns, K.D., Evidence of apoptosis in human diabetic kidney (2004) Mol. Cell. Biochem, 259, pp. 67-70Baba, K., Involvement of apoptosis in patients with diabetic nephropathy: A study on plasma soluble Fas levels and pathological findings (2004) Nephrology (Carlton), 9, pp. 94-99Liaw, P.C., Patients with severe sepsis vary markedly in their ability to generate activated protein C (2004) Blood, 104, pp. 3958-3964Macias, W.L., New insights into the protein C pathway: Potential implications for the biological activities of drotrecogin alfa (activated) (2005) Crit. Care, 9 (SUPPL. 4), pp. S38-S45Glaser, C.B., Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation (1992) J. Clin. Invest, 90, pp. 2565-2573Boehme, M.W., Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: In vivo and in vitro studies (1996) Immunology, 87, pp. 134-140Mosnier, L.O., Gale, A.J., Yegneswaran, S., Griffin, J.H., Activated protein C variants with normal cytoprotective but reduced anticoagulant activity (2004) Blood, 104, pp. 1740-1744Bernard, G.R., Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis (2003) Crit. Care, 7, pp. 155-163Taylor, F.B., Kinasewitz, G., Activated protein C in sepsis (2004) J. Thromb. Haemost, 2, pp. 708-717Chae, S.S., Proia, R.L., Hla, T., Constitutive expression of the S1P1 receptor in adult tissues (2004) Prostaglandins Other Lipid Mediat, 73, pp. 141-150Virag, L., Szabo, C., The therapeutic potential of poly(ADP-ribose) polymerase inhibitors (2002) Pharmacol. Rev, 54, pp. 375-429Cipriani, G., Nuclear poly(ADP-ribose) polymerase-1 rapidly triggers mitochondrial dysfunction (2005) J. Biol. Chem, 280, pp. 17227-17234Alano, C.C., Kauppinen, T.M., Valls, A.V., Swanson, R.A., Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations (2006) Proc. Natl. Acad. Sci. USA, 103, pp. 9685-9690Szabo, C., Biser, A., Benko, R., Bottinger, E., Susztak, K., Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice (2006) Diabetes, 55, pp. 3004-3012Kiss, L., The pathogenesis of diabetic complications: The role of DNA injury and poly(ADP-ribose) polymerase activation in peroxynitrite-mediated cytotoxicity (2005) Mem. Inst. Oswaldo Cruz, 100 (SUPPL. 1), pp. 29-37Richardson, M.A., Gerlitz, B., Grinnell, B.W., Enhancing protein C interaction with thrombin results in a clot-activated anticoagulant (1992) Nature, 360, pp. 261-264Chen, M., Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease (2000) Nat. Med, 6, pp. 797-801Isermann, B., Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis (2001) J. Clin. Invest, 108, pp. 537-546Kerlin, B.A., Survival advantage associated with heterozygous Factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia (2003) Blood, 102, pp. 3085-3092Calkin, A.C., PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse (2006) Nephrol. Dial. Transplant, 21, pp. 2399-2405Mundel, P., Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines (1997) Exp. Cell Res, 236, pp. 248-258Asanuma, K., Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform-specific manner (2005) J. Clin. Invest, 115, pp. 1188-119